左旋氨氯地平联合厄贝沙坦治疗原发性高血压合并左心室肥厚患者的临床疗效  

Clinical efficacy of levamlodipine combined with irbesartan in the treatment of patients with essential hypertension complicated with left ventricular hypertrophy

作　　者：吴海松[1] 刘欣卉 杨东妮[1] WU Haisong;LIU Xinhui;YANG Dongni(Department of Cardiology,Shenyang Red Cross Hospital,Shenyang,Liaoning,110013,China;Liaoning University of Traditional Chinese Medicine,Shenyang,Liaoning,110847,China)

机构地区：[1]沈阳市红十字会医院心内科,辽宁沈阳110013 [2]辽宁中医药大学,辽宁沈阳110847

出　　处：《当代医学》2023年第20期29-32,共4页Contemporary Medicine

基　　金：沈阳市科学技术计划项目(19-110-4-28)。

摘　　要：目的探究左旋氨氯地平联合厄贝沙坦治疗原发性高血压合并左心室肥厚患者的临床疗效。方法选取2020年4月至2021年4月本院收治的92例原发性高血压合并左心室肥厚患者作为研究对象,采用随机数字表法分为对照组与观察组,每组46例。对照组接受常规药物治疗,观察组接受左旋氨氯地平联合厄贝沙坦治疗,比较两组临床疗效、并发症发生率、血压指标及心功能指标。结果观察组治疗总有效率为97.93%,高于对照组的82.61%,差异有统计学意义(P<0.05)。观察组并发症发生率为4.35%,低于对照组的17.39%,差异有统计学意义(P<0.05)。治疗后,观察组收缩压(SBP)、舒张压(DBP)水平均低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组室间隔厚度(IVST)、后壁厚度(PWT)均薄于对照组,左心室舒张末期内径(LVDd)短于对照组,左心室质量指数(LVMI)低于对照组,差异有统计学意义(P<0.05)。结论左旋氨氯地平联合厄贝沙坦治疗原发性高血压疾病合并左心室肥厚患者疗效显著,可改善患者血压指标与心功能指标,安全性较高,值得临床推广应用。Objective To explore the clinical efficacy of levoamlodipine combined with irbesartan in the treatment of patients with essential hy-pertension complicated with left ventricular hypertrophy.Methods 92 patients with essential hypertension complicated with left ventricular hypertro-phy admitted to our hospital from April 2020 to April 2021were selected as the research subjects,and they were divided into the control group and the observation group according to random number table method,with 46 cases in each group.The control group received routine drug treatment,while the observation group received levoamlodipine combined with irbesartan treatment,the clinical efficacy,complication rate,blood pressure in-dex and cardiac function index were compared between the two groups.Results The total effective rate in the observation group was 97.93%,which was higher than 82.61%in the control group,and the difference was statistically significant(P<0.05).The incidence of complications in the observa-tion group was 4.35%,which was lower than 17.39%in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of systolic blood pressure(SBP)and diastolic blood pressure(DBP)in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,interventricular septal thickness(IVST)and posterior wall thickness(PWT)in the observation group were lower than those in the control group,left ventricular end diastolic dimension(LVDd)was shorter than that in the control group,left ventricular mass index(LVMI)was lower than that in the control group,the differences were statistically significant(P<0.05).Conclusion Levamlodipine combined with irbesartan is effective in the treatment of patients with essential hypertension complicated with left ventric-ular hypertrophy,which can improve the blood pressure index and cardiac function index,and is safe and worthy of clinical promotion and application.

关 键 词：原发性高血压 左心室肥厚患者 左旋氨氯地平 厄贝沙坦 

分 类 号：R544.11[医药卫生—心血管疾病] R587.1[医药卫生—内科学]